KR20100109664A - Composition for preventing or treating of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphor as active ingredients - Google Patents

Abstract

PURPOSE: A composition containing camphor for preventing or treating obesity, fatty liver or insulin resistance syndrome is provided to reduce total cholesterol concentration. CONSTITUTION: A composition for preventing or treating metabolic diseases including obesity, dyslipidemia, fatty liver and insulin resistance syndrome contains camphor as an active ingredient. The dyslipidemia is hyperlipidemia. The camphor is derived from plants.

Description

Composition for Preventing or Treating of Obesity, Dyslipidemia, Fatty Liver or Insulin Resistance Syndrome Comprising Camphor as Active Ingredients}

The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising a camphor as an active ingredient.

Due to the change in living environment, the visceral fat type obesity of modern people increases, and the onset of metabolic disease accompanying diabetes, hypertension, lipid metabolism abnormality, insulin resistance, etc. is increasing rapidly. These diseases increase the risk of mutual development and are common diseases associated with multiple metabolic changes such as aging, stress, and immune dysfunction.

According to the 2005 National Health and Nutrition Survey, 32% of Korean adults aged 20 and over were obese (35.2% of adult men and 28.3% of women). The incidence of childhood obesity in Korea has also increased rapidly.In 2005, 11.3% of elementary school students, 10.7% of middle school students, and 16% of high school students were classified as obese (BMI ≥ 25 kg / m ² ), and overweight (BMI ≥ 23 kg / m ^2). Or 17% of obese adolescents have metabolic disease.

This increase in overweight and obesity leads to an increase in the prevalence of chronic diseases, such as high blood pressure (30.2% male, 25.6% male), diabetes (9.0% male, 7.2% female), and high cholesterol in Koreans aged 30 and over in 2005. The prevalence of bloodemia (7.5% male and 8.8% female) is very high compared to other countries. In 2005, the mortality rate from diabetes was 35.5 per 100,000 people in Korea, more than 3-7 times higher than in Japan (5.9), the UK (7.5), or Germany (16.6). The increase in the number of diabetic patients in Korea is expected to increase to 3,000,000 and to 5,450,000 by 2030, which means that 10% of Koreans will become diabetic.

According to the statistics of the Korea Institute of Health and Social Affairs, the socioeconomic losses from obesity and obesity complications in 2006 are estimated to total KRW 2.1 trillion, including indirect expenses such as medical expenses and income loss from treatment. Accordingly, the government sets the main goal of national health promotion in 2010 to reduce adult obesity rate to less than 20% and adolescent obesity rate to less than 15%, and precisely define obesity and metabolic diseases as an implementation strategy to achieve the goal. And the method of measurement was decided.

Efficacy products are imported and sold in Korea in a large amount as a major obesity treatment. Among them, anti-obesity products such as xenical, reductyl, and excori are widely known. Xenical, which is an orlistat-based ingredient, is the world's first anti-obesity agent that inhibits the action of lipase to inhibit fat absorption, decreases total cholesterol and LDL cholesterol levels, improves blood sugar and lowers blood pressure. see. Reductil, the main ingredient of sibutramine (sibutramine), was approved by the FDA in 1997 and is sold in more than 30 countries around the world.It maintains high levels of serotonin and noradrenaline in the sympathetic nervous system, inducing sympathetic nervousness, appetite and satiety There is this. Lastly, Exorix is a non-prescription semi-finished product imported from France, increases heat generation, increases the body's basic metabolism, inhibits lipase activity, reduces intestinal fat absorption by 30%, and increases the production of noradrenaline. There is an action to increase.

Obesity can be the best treatment effect in combination with diet therapy, exercise therapy and behavioral therapy, but this method takes a lot of time and effort and difficult to implement, so many obesity treatments or diet products are used. However, Olistat, which is currently used as a treatment for obesity, has side effects such as fatty stool, intestinal gas generation, and bloating. Sibutramine is known to have side effects such as headache, dry mouth, anorexia, insomnia, and constipation. Orlistat also inhibits the absorption of vitamin E and vitamin D, while phentermine and sibutramine have side effects that lead to increased heart rate, palpitations, or dizziness.

In addition, diabetes mellitus, such as hyperglycemia due to lack of insulin action persists in the high risk of vascular complications, the number of patients steadily increases due to aging and lifestyle changes. The number of diabetics in the world was 30 million in 1985, but it is expected to increase to about 220 million by 2010. In particular, the number of diabetics in industrialized countries is estimated to be 10% of the population. . According to data from the Korea Institute of Science and Technology Planning, the global market for diabetes drugs in 2005 was 12.1 billion dollars, an increase of 12% year-on-year, and the US blood glucose and insulin market was $ 2.6 billion in 2004 and $ 3 billion in 2005. It increased more than 15% compared to the previous year. According to the IDF report, the global diabetes drug market is expected to grow by about 25 percent by 2025. According to the ADA report, indirect and direct medical costs for type 2 diabetes in the US in 2002 are estimated at more than $ 132 billion.

In the case of current type 2 diabetes, reevaluated metformin and thiazolidinedione (TZD) drugs have shown considerable usefulness. In addition, many side effects have also been reported. Therefore, it is necessary to develop more effective and safe drugs that can fundamentally solve insulin resistance. The ultimate therapeutic goal of current diabetes treatments is to maintain normal blood glucose levels. This can be seen from various experiments that most diabetic complications are caused by metabolic failure due to persistent hyperglycemia, and complications can be prevented and delayed by strict blood glucose control in animals and clinical trials. Diabetes treatment drugs used in the clinic are roughly classified into 1) drugs that promote insulin secretion, 2) drugs that enhance the sensitivity of insulin receptors, and 3) drugs that inhibit absorption by inhibiting glycolysis. Insulin preparations exhibit the same physiological activity as insulin in vivo, but are inconvenient to be administered by injection, and insulin resistance is a problem, and sulfonylurea-based drugs (glibenclamide, glyphide ( glipizide, gliquidone, etc.) are oral and inexpensive, but have problems such as hypoglycemia and loss of insulin secretion. Gitazone-based drugs (troglitazone, pioglitazone, rosiglitazone, etc.) complain of side effects such as heart failure, anemia, or liver failure. There is an urgent need for the development of medicines that can be secured at the same time.

As Western medicine shows limitations in overcoming the side effects and chronic diseases of synthetic drugs, the value of new natural products is emerging. Therefore, the present inventors came to pay attention to camphor, which is a monoterpene compound contained in various plants in the process of searching for an active substance that suppresses obesity from native plants.

Camphor (Camphor) is a vegetable essential oil component of the monoterpenes (monoterpene) contained in firewood, persimmon, mulberry, barn, turmeric, Baekdugu, structural formula is C ₁₀ H ₁₆ O, molecular weight is 152.2. Campo is found in large quantities in commercially available liver oil, castor oil, Tiger balm, cold medicine or cough medicine syrup products. Campo has long been used for antiseptic, antipruritic, rubefacient, aphrodisiac, contraceptive, lactation suppressant, etc. still endangering the lives of Canadian children, CAN MED ASSOC J , 152 (11): 1821-1824, 1995). Campo is now included as a flavoring agent in the KFDA Food Additives Database and can be used as a food additive.

U.S. Pat. U.S. Pat.

US Pat. No. 6,871,131 discloses a composition for treating hyperlipidemia comprising phenylacetylglutamine, phenylacetylisoglutamine phenylacetic acid. US Pat. No. 6942967 discloses apobec-1 protein as a therapeutic target for atherosclerosis, hyperlipidemia, obesity and diabetes.

Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

The present inventors have endeavored to develop a natural substance having prophylactic or therapeutic activity against metabolic diseases including obesity, dyslipidemia and / or fatty liver. As a result, the present invention was completed by confirming that the camphor included in various plants had the above activity.

Accordingly, an object of the present invention is to provide a composition for the prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising a camphor as an active ingredient.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

According to an aspect of the present invention, a metabolic disease (metabolic disease) selected from the group consisting of obesity, dyslipidemia, fatty liver and insulin resistance syndrome (Camphor) containing as an active ingredient Prophylactic or therapeutic compositions are provided.

The present inventors have endeavored to develop a natural substance having a prophylactic or therapeutic activity against metabolic diseases including obesity, dyslipidemia and / or fatty liver. As a result, it was found that camphor included in various plants had the above activity.

As demonstrated in the examples below, camphor inhibits adipocyte differentiation, decreases body fat mass, decreases visceral fat mass, decreases total cholesterol concentration, decreases plasma triglycerides and hepatic triglycerides resulting in obesity induced by a high fat diet It has the effect of significantly alleviating the phenomenon. In addition, the camphor results in a significant decrease in fasting blood glucose and blood insulin levels, thereby exerting an effect of improving insulin resistance and of closely related metabolic inflammatory responses.

As used herein, the term “dyslipidemia” is a concept including hyperlipidemia, which appears as a problem such as metabolic abnormalities of lipoproteins in addition to hypercholesterolemia, hypertriglyceridemia, and low HDL-cholesterolemia, which are indicated by an increase in the level of fat in the blood. It means an abnormal lipid state.

As used herein, the term "hyperlipidemia" refers to a disease caused by a large amount of fat in the blood due to poor metabolism of triglycerides and cholesterol. More specifically, hyperlipidemia includes hypercholesterolemia or hypertriglyceridemia with high incidence with increased lipid components such as triglycerides, LDL cholesterol, phospholipids and free fatty acids in the blood.

As used herein, the term “fatty liver” refers to a condition in which fat accumulates in liver cells in excessive amounts due to adipose metabolism disorder of the liver, which causes various diseases such as angina pectoris, myocardial infarction, stroke, arteriosclerosis, fatty liver and pancreatitis. do.

As used herein, the term “insulin resistance” refers to the inability of insulin to lower blood sugar and thus the cells not effectively burning glucose. When insulin resistance is high, the body produces too much insulin, which can lead to high blood pressure or dyslipidemia, as well as heart disease and diabetes. In particular, type 2 diabetes does not notice an increase in insulin in the muscles and adipose tissue, so the action of insulin does not occur.

As used herein, the term "insulin resistance syndrome" is a generic term for the disease caused by insulin resistance, and the cell resistance to insulin action, hyperinsulinemia, very low density lipoprotein (VLDL) and neutral It is a disease characterized by an increase in fat, a decrease in high density lipoprotein (HDL), and high blood pressure, and is a concept recognized as a risk factor for cardiovascular disease and type 2 diabetes (Reaven GM., Role of insulin resistance in human disease, Diabetes , 37: 1595-607 (1988). In addition, insulin resistance, along with risk factors such as hypertension, diabetes, and smoking, is known to increase oxidative stress in the cell and to change the signaling system, leading to inflammatory reactions and progressing atherosclerosis (Freeman BA et al., Biology of disease: free radicals and tissue injury, Lab . Invest . 47: 412-26 (1982) , Kawamura M et al., Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway, J. Clin . Invest . 94: 771-8 (1994).

As used herein, the term “metabolic disease” is a conceptualization of a group of cardiovascular disease and type 2 diabetes risk factors clustered together into one disease group, which includes insulin resistance and various complex metabolic disorders and clinical trials. It is a concept that encompasses all aspects. In 1988, Reaven insisted that the common cause of these symptoms was insulin resistance in the body, and called insulin resistance syndrome. In 1998, the World Health Organization (WHO) explained that all of these symptoms were explained. The term metabolic syndrome or metabolic disease was introduced.

Campo, the active ingredient of the present invention, is a vegetable essential oil component of monoterpene (monoterpene), which is contained in firewood, persimmon, mulberry, barn, turmeric, and baekdu, forms colorless crystals with an irritating smell and taste. ₁₀ H ₁₆ O and a molecular weight of 152.2. The camphor has a structure of (+)-campo represented by the following formula (1) or (-)-campo represented by the formula (2):

Formula 1

Formula 2

The composition containing the camphor of the present invention as an active ingredient has activity to improve various diseases of metabolic syndrome, for example, obesity, dyslipidemia, fatty liver or insulin resistance syndrome. The composition of the present invention can prevent or treat metabolic diseases by various activities. Four exemplary preferred embodiments are described below:

According to a first embodiment, the composition of the present invention significantly reduces adipocyte differentiation, thus exhibiting the prophylactic or therapeutic activity. In one embodiment of the present specification, the composition of the present invention significantly reduced the differentiation of adipocytes in a concentration-dependent manner showed a prophylactic or therapeutic activity of metabolic diseases (see Figure 1).

According to a second embodiment, the composition of the present invention exhibits such prophylactic or therapeutic activity by significantly reducing plasma or liver fat levels, more preferably plasma or liver triglycerides, cholesterol or free fatty acid levels. In one embodiment of the present specification, the composition of the present invention, the plasma triglyceride concentration, total cholesterol concentration, LDL + VDL cholesterol concentration, arteriosclerosis indicator and free fatty acid concentration between the triglyceride concentration, cholesterol concentration and free fatty acid concentration, It was reduced to show the prophylactic or therapeutic activity of metabolic diseases (see Tables 2 and 3).

According to a third embodiment, the composition of the present invention exhibits said prophylactic or therapeutic activity by significantly reducing visceral fat levels, more preferably epididymal fat, peripheral kidney fat, mesenteric fat or celiac fat levels. In one embodiment of the present specification, the composition of the present invention showed a significant reduction in total visceral fat weight, epididymal fat weight, peripheral fat weight, mesenteric fat weight, and posterior abdominal fat weight to show the preventive or therapeutic activity of metabolic diseases. (Note: Figure 3).

According to a fourth embodiment, the composition of the present invention exhibits such prophylactic or therapeutic activity by significantly reducing plasma glucose levels or insulin levels. In one embodiment of the present disclosure, the composition of the present invention exhibited a prophylactic or therapeutic activity of metabolic diseases by lowering fasting blood glucose levels and significantly decreasing blood insulin levels (see Table 2).

According to a preferred embodiment of the present invention, the composition of the present invention is applied for the prevention or treatment of dyslipidemia, more preferably hyperlipidemia.

According to an embodiment of the present disclosure, the plasma triglyceride concentration is 49%, the total cholesterol concentration is 47%, LDL + VLDL cholesterol concentration 46%, free fatty acid concentration compared to the high fat diet group when administering the composition of the present invention Decreased by 86%, showing an excellent effect on dyslipidemia, especially hyperlipidemia caused by metabolic diseases (see Table 2).

According to a preferred embodiment of the present invention, the composition of the present invention is for the prevention of insulin resistance syndrome, more preferably obesity, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia, nonalcoholic fatty liver or type 2 diabetes due to insulin resistance or Applied to the treatment.

According to one embodiment of the present specification, the administration of the composition of the present invention, compared to the high-fat diet group, the fasting blood sugar was reduced by more than 22%, the blood insulin concentration also showed a 29% significant decrease, insulin resistance index (insulin resistance, IRI) also showed a 44% reduction in the effects of improving insulin resistance syndrome and its closely related metabolic diseases (see Table 2).

According to a preferred embodiment of the present invention, the camphor is included in the extract or fraction of the plant.

Plants used in the present invention is not particularly limited as long as it contains a camphor, preferably camphor is firewood, persimmon, mulberry, barn, turmeric, Baekdugu,Achillea Filip Pendulina(Achillea filipendulina, Fernleaf Yarrow),Achillea Millepolium(Achillea millefolium, Carpenter's Weed),Acorus Calamus(Acorus calamus, Calamus Phizome),Alpinia Galanga(Alpinia galanga, Chinese Ginger),Alpinia Officina Room(Alpinia officinarum, Chinese Ginger),Dark Visnaga(Ammi visnaga, Pick Tooth),Anetum Graveorens(Anethum graveolens, Dill),Anoa Squamous(Annona squamosa, Custard apple),Annika Montana(Arnica montana, Arnica),Artemisia ANNOA(Artemisia annua, Annual mugwort),Artemisia Iwayo Mosquito(Artemisia iwayomogi),Artemisia Dragoonculus(Artemisia dracunculus, French Tarragon),Artemisia Bulgarias(Artemisia vulgaris, Chinese moxa),Blumea Balmifera(Blurmea balsamifera, Ngai camphor),Voldea Fragrance(Boldea fragrans, Boldo),Cannabis Sativa(Cannabis sativa, Hemp),Capsicum Fructessense(Capsicum frutescens, African pepper),Centella Asa Attica(Centella asiatica, Asiatic pennywort),Chrysanthemum Parthenium(Chrysanthemum parthenium, Bachelor's buttons),Cinnamomum Berum(Cinnamomum verum, Ceylon Cinnamon),Korean Room Sativa(Coriandrum sativum, Chinese Parsley),Crocus Sativa(Crocus sativus, Asian Saffron),Curcuma Longa(Curcuma longa, Common turmeric),Doucus Carota(Daucus carota, Carrot),Eletaria Serdamomum(Elettaria cardamomum, Cardamom),Elsault Gia Celiaata(Elsholtzia ciliata, Elsholtzia),Poenikul Room Bulgare(Foeniculum vulgare, Bitter fennel),Glishriza Glabra(Glycyrrhiza glabra, Commom Licorice),Helianthus Annus(Helianthus annuus, Annual Sunflower),Hisofus Officialis(Hyssopus officinalis, Azob),Inul Hellenium(Inula helenium, Elecampane),Juniperus Communis(Juniperus communis, Common Juniper),Lactuca Virosa(Lactuca virosa, Bitter Lettuce),Lantana Camara(Lantana camara, Bahama tea),Larea Tridenta(Larrea tridentata, chaparral),Laurus Nobilis(Laurus nobilis, Bay),Labandula Angustivolia(Lavandula angustifolia, Common Lavender),Labandula Latifolia(Lavandula latifolia, Aspic),Labandula Intermedia(Lavandula x intermedia, Bastard lavender),Levisticum Officenale(Levisticum officinale, Lovage),Ripia Dulcis(Lippia dulcis),Magnolia Cobus(Magnolia kobus, Hsin-I),Melaleuca Alternifolia(Melaleuca alternifolia, Narrow-leaved paperback tea-tree),Myristica Fragrance(Myristica fragrans, Mace),Myrtus Communis(Myrtus communis, Common myrtle),Nefeta Cataria(Nepeta cataria, Cat-mint),Osimum Vasilycum(Occimum basilicum, Basil),Osimum Gratissimum(Occimum gratissimum, African basil),Duck Garum Onites(Origanum onites, Oregano),Duck Garum Syriakum(Origanum syriacum, Bible hyssop),Duck Garum Bulgare(Origanum vulgare, Common marjoram),Pimenta Acris(Pimenta acris, Bay),Pimfinella Annisum(Pimpinella anisum, Anise),Pinus Sylvesters(Pinus silvestris, Pine),Piper Nigrum(Piper nigrum, Black Pepper),Polium Erectum(Polium erectum, Germander),Polygonum Hydropipe(Polygonum hydropiper, Common Smartweed),Petico Petal Room Olkoides(Ptychopetalum olacoides, Muira puama),Rosemarinus Officialis(Rosmarinus officinalis, Compass Plant),Salvia Fruitico(Salvia fruticosa, Greek oregano),Salvia Officialis(Salvia officinalis, Broadleaf sage),Salvia Officialis Purpurasense(Salvia officinalis purpurascens, Common Sage purpurascens),Salvia Pratensis(Salvia pratensis, Meadow Clary),Salvia Scrare(Salvia sclarea, Clary),Sasapras Alvidum(Sassafras albidum, Ague tree),Saturza Hortensis(Satureja hortensis, Garden Savory Plant),Saturza Montana(Satureja montana, Savory),Stevia Rebaudiana(Stevia rebaudiana, Honey Leaf),Teukurium Scorodonia(Teucrium scorodonia, Germander),Investment(Thuja occidentalis, American arbor-vitae),Timus Mastikina(Thymus mastichina, Mastic thyme),Timus Bulgari(Thymus vulgaris, Common Thyme),Timus Citriodorus(Thymus x citriodorus, Funk's thyme),Timus Gigis(Thymus zygis, Spanish thyme),Valerian Officialis(Valeriana officinalis, Common Valerian),Vitex Agnus Castus(Vitex agnus castus, Agnus castus) orJingiber Officenale(Zingiber officinale, Ginger) can be extracted or fractionated using a plant.

Plant extracts containing camphor may be obtained using conventional extraction solvents for the plants, preferably (a) anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (e.g. methanol, ethanol, propanol, butanol, normal- Propanol, iso-propanol and normal-butanol, etc.), (b) the mixed solvent of the lower alcohol with water, (c) acetone, (d) ethyl acetate, (e) chloroform, (f) 1,3-butylene Glycol, (g) hexane, (h) diethyl ether, (i) butyl acetate or (j) water can be obtained as an extraction solvent.

Plant fraction comprising camphor refers to a more isolated / purified form obtained by further separating / purifying the plant extract. For example, fractions obtained by passing the plant extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods are also included in plant fractions containing camphor.

In addition, said camphor can be synthesize | combined chemically.

According to a preferred embodiment of the present invention, the camphor includes a camphor prepared synthetically in addition to the separation from the plant.

According to another aspect of the invention, the present invention provides a pharmaceutical composition or food composition for the prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising a camphor.

When the composition of the present invention is made into a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like It doesn't happen. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention may be administered orally or parenterally, and preferably applied by oral administration.

Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be. Preferred dosages of the pharmaceutical compositions of the invention are in the range of 0.001-100 mg / kg on an adult basis.

The pharmaceutical compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container. The formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of extracts, powders, powders, granules, tablets or capsules, and may further comprise dispersants or stabilizers.

When the composition of the present invention is made of a food composition, it contains not only camphor as an active ingredient, but also components commonly added during food production, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents. Include. Examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As the flavoring agent, natural flavoring agents [tautin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

For example, when the food composition of the present invention is prepared with a drink, in addition to camphor which is the active ingredient of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, tofu extract, jujube extract, licorice extract, etc. You can.

The features and advantages of the present invention are summarized as follows.

(Iii) The present invention provides a composition for the prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising a camphor as an active ingredient.

(Ii) The composition of the present invention can be separated using various plants and can be synthesized through chemical methods.

(Iii) The composition of the present invention comprising a camphor as an active ingredient causes inhibition of adipocyte differentiation, a decrease in body fat amount, a decrease in visceral fat amount, a decrease in total cholesterol concentration, a decrease in plasma triglycerides and hepatic triglycerides, Ultimately, it exhibits prophylactic or therapeutic activity for obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention results in a significant decrease in fasting blood glucose and blood insulin levels, thereby exerting an effect of improving insulin resistance and an effect of improving metabolic diseases closely related thereto.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example

Example 1: Adipose cell differentiation inhibitory effect of camphor using mouse adipocyte line (3T3-L1)

Cell Culture and Oil Red O Staining

Mouse fat cell line (3T3-L1) was used to evaluate the effect of camphor on the differentiation and growth of adipocytes. Adipocytes, 3T3-L1 cells, were dispensed in 12-well plates and added Dulbecco-modified Eagle with 1% penicillin-streptomycin, 1% non-essential amino acids, and 10% fetal bovine serum (FBS). medium) was used to incubate in a confluent state at 37 ℃, 5% CO ₂ incubator. Confluent and grown 3T3-L1 cells were cultured for two days in a medium containing MDI (0.5 mM isobutyl-methylxanthine, 1 μM dexamethasone and 1 μg / ml insulin) and differentiated. After making adipocytes (differentiation adipocytes), the cells were differentiated into mature adipocytes while incubated for two more days in a DMEM medium containing 1 μg / ml insulin. Thereafter, the cells were incubated for 10 days while replacing the DMEM medium every two days to form fully differentiated adipocytes.

Camppo was treated in culture at concentrations of 0.1, 1, 10, 50 and 100 μM at two-day intervals from the first day of differentiation by adding MDI to 3T3-L1 cells. (±) -campo was purchased from Aldrich (Sigma-Aldrich), dissolved in DMSO, and negative control group containing only DMSO was included in the experiment. After 14 days of incubation, the culture solution was removed at the time of differentiation, and the fat globules contained in the differentiated adipocytes were stained. To do this, wash the cells twice with PBS (phosphate buffered saline), fix the cells with 10% buffered neutral formalin (BNF) for 1 hour, wash once again with PBS, and then oil red specifically to stain the fat. 1 ml of O dye was added to a 12-well plate to stain the fat globules for 1 hour and washed twice with distilled water.

In order to measure the concentration of triglycerides contained in the differentiated 3T3-L1 cells, stained fat globules were dissolved in 1 ml of isobutanol, and the O.D values were measured at 600 nm.

Camphor's ability to inhibit adipocyte differentiation

As shown in FIG. 1A, the treatment of camphor to 3T3-L1 cells significantly reduced the differentiation of adipocytes in a concentration-dependent manner. The amount of intracellular fat stained with oil red O was quantified by spectrophotometry, which also reduced the O.D value in a concentration dependent manner (FIG. 1B).

Example 2: Body weight and visceral fat reduction effect of the camphor using a mouse Experimental diet preparation and breeding of laboratory animals

The obesity induction diet used in this experiment was a high-fat diet (hgh-fat diet, HFD: 40% calorie, 17 g lard + 3% corn oil / 100 g diet). The same but with a camphor level of 0.2%. Normal diet (ND) was prepared based on the composition of the AIN-76 rodent diet (American Institute of Nutrition, Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. J. Nutr. 107: 1340-1348, 1977). (Table 1). (±) -campo was purchased from Aldrich (Sigma-Aldrich).

Experimental composition table ingredient Normal diet (ND)
(g / kg diet) Control Diet (HFD)
(g / kg diet) Campor
(g / kg diet) Casein 200 200 200 DL-Methionine 3 3 3 Corn starch 149.99 110.96 108.96 Sucrose 500 370 370 cellulose 50 50 50 Corn oil 50 30 30 Laad - 170 170 Vitamin complex 10 12 12 Mineral complex 35 42 42 Choline Bitartrate 2 2 2 cholesterol - 10 10 tert-butyhydroquinone 0.01 0.04 0.04 Campo - - 2.00 Total (g) 1,000 1,000 1,000 Fat (% calories) 11.5 39.0 39.0 Total calories, kJ / kg diet 16,439 19,315 19,315

Five-week-old male C57BL / 6J mice (Orient, Korea) were adapted to the laboratory environment for 1 week with solid feed, and then randomly placed into the high fat diet control group and the experimental group according to the egg mass method, and reared for 10 weeks. The diet was fed with water between 10 and 11 am daily, and dietary intake was measured daily and body weight was measured every three days. In order to prevent sudden weight change due to feed intake, body weight was measured 2 hours after removing the feed container, and the dietary efficiency was the total test period from the feeding date to the sacrifice day, and the cumulative weight gain during the test period was determined by the total diet. Calculated by dividing by intake. After fasting the test animals for 12 hours or more, blood, liver, and visceral fat tissue (diplordial fat, perirenal fat, mesenteric fat, and abdominal fat) were collected under anesthesia with diethyl ether to prepare 0.1 M phosphate buffer solution (pH). 7.4), and then weighed. Blood collected from the abdominal aorta was centrifuged at 1000 x g for 15 minutes to separate plasma.

Body weight and visceral fat weight

The final weight and the weight gain of the 10 weeks after ingesting the experimental diet for 10 weeks, compared to the high-fat diet control group (HFD), 27% of the final weight and 42% of the cumulative weight gain in the group fed the camphor. Significantly decreased (FIG. 2).

After 10 weeks of intake of the experimental diet, body weight vs. epididymal fat, peripheral fat, mesenteric fat, and posterior cavity fat were measured, and as a result, 39% of epididymal fat per unit weight was found in the campo group compared to the control (HFD). The peripheral fat weight was 65%, the mesenteric fat weight 36%, the posterior abdominal fat weight 39%, and the total visceral fat weight 40% ( P <0.001) (Figs. 3 and 4). Therefore, it was confirmed that the camphor has a very excellent weight loss and visceral fat reduction effect.

Example  3: Campo Obesity  Hyperlipidemia, fatty liver Type 2 diabetes  Prevention and Treatment Benefits

Plasma total cholesterol, triglyceride and glucose concentration were measured twice each using a commercial clinical kit (Bio Clinical system), insulin concentration was measured by ELISA using a mouse insulin kit (Shibayaki, Japan). The lipid component of liver tissue was extracted according to the method of Folch et al. 1 mL of distilled water was added to 0.25 g of liver tissue and homogenized using a polytron homogenizer (IKA-WERKE GmbH & Co., Ultra-Turrax, Staufen, Germany). 5 mL of a chloroform: methanol solution (2: 1, v / v) was added to the homogeneous solution, and the mixture was mixed well, followed by centrifugation at 1000 xg for 10 minutes to separate the lower layer solution, and the chloroform: methanol solution (2: 1, v / v) 2 mL was added, and the same procedure was repeated to completely separate the liver lipid components. 3 mL of chloroform: methanol: 0.05% CaCl ₂ (3:48:47, v / v / v) solution was added to the lower layer solution, mixed for 1 minute, and centrifuged at 1000 xg for 10 minutes. After completely drying with nitrogen gas, the dried lipid was dissolved in 1 mL of methanol and used for lipid component analysis. Triglyceride concentrations in hepatic lipid extracts were measured using the same commercial lipid analysis kit (Bio Clinical system) used for the analysis of plasma.

Plasma lipid concentrations of mice fed the experimental diet shown in Table 1 for 10 weeks were 49% triglyceride, 47% total cholesterol, and LDL + VLDL cholesterol in the campo group compared to the high-fat diet control (HFD). The concentration was 46% and the free fatty acid concentration was significantly decreased by 86% (Table 2). In addition, ingestion of camphor resulted in a 22% reduction in fasting blood glucose as well as a 29% reduction in blood insulin levels and a 44% decrease in insulin resistance index (IRI) compared to the high-fat diet control group. Table 2). Therefore, camphor has the effect of improving type 2 diabetes or insulin resistance, and is also expected to improve the metabolic inflammatory response closely related thereto.

Obesity-related Biochemical Indicators of Mouse Blood Containing Camphor Normal diet.
( ND ) High Fat Diet Control Group
( HFD ) Campo food.
( Camphor ) Triglyceride ( mmol / L) 0.60 ± 0.09 ^b 1.41 ± 0.12 ^a 0.72 ± 0.11 ^b Total Cholesterol ( mmol / L) 1.96 ± 0.03 ^b 3.83 ± 0.32 ^a 2.02 ± 0.13 ^b HDL  cholesterol( mmol / L) 1.42 ± 0.03 ^b 1.78 ± 0.07 ^a 0.92 ± 0.04 ^c LDL + VLDL  cholesterol ( mmol / L) 0.54 ± 0.02 ^b 2.05 ± 0.25 ^a 1.10 ± 0.12 ^b Free fatty acid ( uEq / L) 573 ± 40 ^b 1417 ± 128 ^a 202 ± 11 ^c glucose( mmol / L) 6.17 ± 0.95 ^b 8.49 ± 0.53 ^a 6.63 ± 0.31 ^b insulin( ng Of mL ) 0.72 ± 0.06 ^b 1.26 ± 0.02 ^a 0.90 ± 0.07 ^b IRI ^{One )} 0.79 ± 0.31 ^b 1.84 ± 0.24 ^a 1.03 ± 0.29 ^b

Different letters within the same row exhibit significant difference at P <0.05 by one-way ANOVA followed by Duncan's multiple range test.

¹⁾ Insulin resistance index (IRI) = 10 ^-3 pmol insulin X mmol glucose XL ^-2

The liver weight of the rats fed the experimental diet for 10 weeks was significantly reduced by 24% in the campo intake group compared to the high-fat diet control group. The lipid concentrations of liver tissues were significantly lower in triglyceride concentration, 53% cholesterol, 80% cholesterol, and 71% free fatty acid concentration than those of high fat diet control group (Table 3). Therefore, it can be seen that the camphor significantly relieves fatty liver phenomenon in high fat diet-induced obesity, and significantly improves obesity inflammation and insulin resistance in the liver tissue.

Obesity-related Biochemical Indicators of Mouse Liver Tissue Ingested with Campo Normal diet.
( ND ) High Fat Diet Control Group
( HFD ) Campo food.
( Camphor ) Liver weight (g / 100 g body wt ) 3.6 ± 0.14 ^b 5.5 ± 0.32 ^a 4.2 ± 0.37 ^b Triglyceride (μ mol / g) 20.3 ± 1.21 ^b 35.0 ± 1.22 ^a 16.3 ± 2.6 ^c Cholesterol (μ mol / g) 21.6 ± 0.58 ^b 74.8 ± 0.68 ^a 15.1 ± 2.99 ^c Free fatty acid ( uEq / g) 8.6 ± 1.13 ^b 24.3 ± 0.86 ^a 7.07 ± 1.42 ^b

Different letters within the same row exhibit significant difference at P <0.05 by one-way ANOVA followed by Duncan's multiple range test.

Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Figure 1a-1b is a diagram showing the effect of inhibiting the differentiation of camphor in 3T3-L1 cells.

2 is a diagram showing the body weight and weight gain of the mice ingested the experimental diet. In the line or bar graph, gray represents the normal diet group (ND), black represents the high-fat diet control group (HFD), and pink represents the campo-administered group, and letters a to c represent analysis of variance (ANOVA) and Duncan. By Duncan's multiple range test, P <0.001 level showed statistically significant difference between experimental groups.

3 is a diagram showing the weight vs. epididymal fat, peripheral kidney fat, mesenteric fat, celiac fat and total visceral fat weight of mice fed the experimental diet. In the bar graph, gray represents the normal diet group (ND), black represents the high-fat diet control group (HFD), and pink represents the campo-administered group, and letters a through c represent P by variance analysis (ANOVA) and Duncan's multi-range test. At the level <0.001, there is a statistically significant difference between the experimental groups.

Figure 4 is a picture of visceral fat mass for each part of the mouse ingested the experimental diet. In the figure, Epididymal fat represents epididymal fat, Mesenteric fat represents mesenteric fat, Retroperitoneal fat represents retroperitoneal fat, and Perirenal fat represents peripheral fat.

Claims (12)

Composition for the prevention or treatment of metabolic disease (metabolic disease) selected from the group consisting of obesity, dyslipidemia, fatty liver and Insulin resistance syndrome containing a Campo (effective) as an active ingredient. The composition of claim 1, wherein the dyslipidemia is hyperlipidemia. The composition of claim 1, wherein the insulin resistance syndrome comprises one or more diseases selected from the group consisting of insulin resistance obesity, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia, and nonalcoholic fatty liver. . The composition of claim 1, wherein the prevention or treatment reduces adipocyte differentiation. The composition of claim 1, wherein the prevention or treatment reduces plasma, liver or visceral fat levels. 6. The composition of claim 5 wherein said fat comprises triglyceride, cholesterol or free fatty acid. 6. The composition of claim 5, wherein the visceral fat comprises one or more fats selected from epididymal fat, perirenal fat, mesenteric fat, and celiac fat. The composition of claim 1, wherein the prophylaxis or treatment reduces glucose levels in plasma. The composition of claim 1, wherein the prophylaxis or treatment reduces the insulin levels of plasma. (a) a therapeutically effective amount of the composition of claim 1; And (b) a pharmaceutical composition for the prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising a pharmaceutically acceptable carrier. (a) a food-effective amount of the composition of claim 1; And (b) a food composition for improving obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising a food acceptable carrier. 12. The composition of claim 1, 10 or 11, wherein the camphor is derived from a plant containing camphor.

Images